The Evolving Landscape of Predictive Biomarkers in Immuno-Oncology With a Focus on Spatial Technologies Publisher



Sadeghi Rad H¹ ; Bazaz SR² ; Monkman J^{3, 4} ; Ebrahimi Warkiani M^{2, 5} ; Rezaei N^{1, 6, 7} ; Obyrne K^{3, 4, 8} ; Kulasinghe A^{3, 4, 9} Show Affiliations
Source: Clinical and Translational Immunology Published:2020

Abstract

Immunotherapies have shown long-lasting and unparalleled responses for cancer patients compared to conventional therapy. However, they seem to only be effective in a subset of patients. Therefore, it has become evident that a greater understanding of the tumor microenvironment (TME) is required to understand the nuances which may be at play for a favorable outcome to therapy. The immune contexture of the TME is an important factor in dictating how well a tumor may respond to immune checkpoint inhibitors. While traditional immunohistochemistry techniques allow for the profiling of cells in the tumor, this is often lost when tumors are analysed using bulk tissue genomic approaches. Moreover, the actual cellular proportions, cellular heterogeneity and deeper spatial distribution are lacking in characterisation. Advances in tissue interrogation technologies have given rise to spatially resolved characterisation of the TME. This review aims to provide an overview of the current methodologies that are used to profile the TME, which may provide insights into the immunopathology associated with a favorable outcome to immunotherapy. © 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.